FDC Past Earnings Performance
Past criteria checks 5/6
FDC has been growing earnings at an average annual rate of 0.9%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 10.8% per year. FDC's return on equity is 14.7%, and it has net margins of 15.1%.
Key information
0.9%
Earnings growth rate
2.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 10.8% |
| Return on equity | 14.7% |
| Net Margin | 15.1% |
| Next Earnings Update | 29 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How FDC makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 19,157 | 2,897 | 5,075 | 0 |
| 30 Sep 23 | 18,668 | 2,512 | 4,991 | 0 |
| 30 Jun 23 | 18,255 | 2,332 | 3,986 | 0 |
| 31 Mar 23 | 17,838 | 1,940 | 4,890 | 0 |
| 31 Dec 22 | 16,900 | 1,738 | 4,551 | 0 |
| 30 Sep 22 | 16,225 | 1,687 | 4,421 | 0 |
| 30 Jun 22 | 15,751 | 1,893 | 3,491 | 0 |
| 31 Mar 22 | 15,279 | 2,164 | 4,268 | 0 |
| 31 Dec 21 | 15,003 | 2,522 | 3,759 | 0 |
| 30 Sep 21 | 14,987 | 2,918 | 3,734 | 0 |
| 30 Jun 21 | 14,725 | 3,075 | 3,235 | 0 |
| 31 Mar 21 | 13,332 | 3,013 | 3,353 | 0 |
| 31 Dec 20 | 13,531 | 3,106 | 3,505 | 0 |
| 30 Sep 20 | 13,341 | 3,094 | 3,403 | 0 |
| 30 Jun 20 | 13,089 | 2,754 | 2,757 | 0 |
| 31 Mar 20 | 13,442 | 2,399 | 3,344 | 0 |
| 31 Dec 19 | 12,815 | 2,192 | 3,129 | 0 |
| 30 Sep 19 | 12,165 | 1,909 | 3,013 | 0 |
| 30 Jun 19 | 11,442 | 1,771 | 2,343 | 0 |
| 31 Mar 19 | 10,907 | 1,698 | 2,772 | 0 |
| 31 Mar 18 | 10,751 | 1,735 | 2,677 | 0 |
| 31 Mar 17 | 10,139 | 1,885 | 2,249 | 0 |
| 31 Mar 16 | 9,943 | 1,687 | 2,049 | 0 |
| 31 Mar 15 | 8,893 | 1,481 | 1,706 | 0 |
| 31 Mar 14 | 8,459 | 1,353 | 2,144 | 0 |
Quality Earnings: 531599 has high quality earnings.
Growing Profit Margin: 531599's current net profit margins (15.1%) are higher than last year (10.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 531599's earnings have grown by 0.9% per year over the past 5 years.
Accelerating Growth: 531599's earnings growth over the past year (66.7%) exceeds its 5-year average (0.9% per year).
Earnings vs Industry: 531599 earnings growth over the past year (66.7%) exceeded the Pharmaceuticals industry 23.8%.
Return on Equity
High ROE: 531599's Return on Equity (14.7%) is considered low.